Drugs / CBS001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05323110 | Apr 2022 → Aug 2023 | — | Capella Bioscience Ltd | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBS001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05323110 ↗ |
| Modality | Monoclonal antibody | “Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.” NCT05323110 ↗ |
| Route | Intravenous | “Intravenously administered” NCT05323110 ↗ |